One move can changethe outcome1For your patients with CKD associatedwith T2D, intervene now to deliverdual cardiorenal risk reduction Learn more > Finerenone (Firialta®) is indicated for treatment ofChronic Kidney Disease (stage 3 and 4) with albuminuriaassociated with type 2 diabetes (T2D)1 CKD=chronic kidney disease; T2D=type 2 diabetes.References: 1. Kerendia European Summary of Product Characteristics (SmPC); February 2023 RELATED DOWNLOAD MATERIALS (329.08 KB) Product Information - 18 March 2025 (262.8 KB) Patient Information Leaflet - 18 March 2025 (2.24 MB) FIDELIO-DKD: Study Design (10.07 MB) The burden of CKD (1.53 MB) The FIDELIO-DKD study included patients with mild-moderate to severe CKD and T2D